A Phase 2, Randomized, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety, of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis

Trial Profile

A Phase 2, Randomized, Placebo-controlled Multi-center Study to Investigate the Efficacy and Safety, of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Ulcerative colitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 May 2018 According to a Celgene Corporation media release, data from this study will be presented at the Digestive Disease Week (DDW) meeting in June 2018.
    • 15 Feb 2018 Results published in the Celgene Corporation media release.
    • 15 Feb 2018 According to a Celgene Corporation media release, data was presented at the 13th Congress of the European Crohn's and Colitis Organization (ECCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top